Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 9/20 | 0.47 |
| ▸ | SSTR1 | P30872 | 7/20 | 0.47 |
| ▸ | SSTR2 | P30874 | 6/20 | 0.42 |
| ▸ | SSTR3 | P32745 | 6/20 | 0.42 |
| ▸ | SSTR5 | P35346 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GPR3 | P46089 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.39 |
| ▸ | CCR4 | P51679 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | GLS | O94925 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30018094 | 0.85 | SSTR4 (0.45) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| SCHEMBL16252850 | 0.85 | SSTR4 (0.45) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| SCHEMBL15730345 | 0.82 | POLB (0.51) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| SCHEMBL31560835 | 0.79 | SSTR4 (0.50) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| SCHEMBL14584040 | 0.78 | PDE4A (0.37) | SSTR4SSTR1KDM4EGPR3CNR2 | |
| SCHEMBL11682472 | 0.78 | KDM4E (0.39) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| SCHEMBL31708031 | 0.78 | SSTR4 (0.43) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| SCHEMBL13145736 | 0.77 | HPGD (0.45) | — | |
| SCHEMBL31560787 | 0.77 | SSTR4 (0.51) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| SCHEMBL22015610 | 0.77 | SSTR4 (0.51) | SSTR4SSTR1SSTR2SSTR3SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-11 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-11807624-B2 | Substituted pyrimidinones as agonists of the APJ receptor | AMGEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807624-B2 | Substituted pyrimidinones as agonists of the APJ receptor | AMGEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| US-20230226040-A1 | COMBINATION THERAPY COMPRISING AN FGFR INHIBITOR AND A KRAS INHIBITOR | INCYTE CORPORATION | 2023-07-20 | — | — | US | disclosed |
| US-20230226040-A1 | COMBINATION THERAPY COMPRISING AN FGFR INHIBITOR AND A KRAS INHIBITOR | INCYTE CORPORATION | 2023-07-20 | — | — | US | disclosed |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20080312435-A1 | Imine Compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-7420055-B2 | Antagonists of the chemokine receptor 9 (CCR9); inhibit TECK ligand; antiinflammatory agents and immunoregulators; inflammatory bowel disease; (2-phenylsulfonamidophenyl)-pyridinyl-methanones; N-[4-chloro-2(pyridine4-carbonyl)-phenyl]4-morpholin-4-yl-benzenesulfonamide | CHEMOCENTRYX, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-7420055-B2 | Antagonists of the chemokine receptor 9 (CCR9); inhibit TECK ligand; antiinflammatory agents and immunoregulators; inflammatory bowel disease; (2-phenylsulfonamidophenyl)-pyridinyl-methanones; N-[4-chloro-2(pyridine4-carbonyl)-phenyl]4-morpholin-4-yl-benzenesulfonamide | CHEMOCENTRYX, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20080161345-A1 | Aryl Sulfonamides | CHEMOCENTRYX, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161345-A1 | Aryl Sulfonamides | CHEMOCENTRYX, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080107625-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080107623-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080107624-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20070099825-A1 | ethyl 2-(biphenyl-4-yl)-6-(tert-butoxycarbonylamino)-2-methoxy-8-(2-nitrophenylsulfonyl)-5,16-dioxo-1,2,3,5,6,7,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[n]pyrrolo[2,1-c][1,4,8]triazacyclopentadecine-14a-carboxylate; viricide; synergistic with other active ingredients | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-03 | — | — | US | disclosed |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CHEMOCENTRYX, INC. | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312435-A1 | Imine Compound | CNR1, CNR2, HRH4 | SSTR4 290/4885SSTR1 133/4885SSTR2 221/4885 |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | SSTR4 2812/4885SSTR1 2123/4885SSTR2 1488/4885 |
| US-20080107623-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, HCCS, VIP | SSTR4 2296/4885SSTR1 2767/4885SSTR2 3073/4885 |
| US-20070099825-A1 | ethyl 2-(biphenyl-4-yl)-6-(tert-butoxycarbonylamino)-2-methoxy-8-(2-nitrophenylsulfonyl)-5,16-dioxo-1,2,3,5,6,7,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[n]pyrrolo[2,1-c][1,4,8]triazacyclopentadecine-14a-carboxylate; viricide; synergistic with other active ingredients | TERT, VIP, YWHAZ | SSTR4 311/4885SSTR1 599/4885SSTR2 857/4885 |
| US-20080107624-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, MRPS23, HCCS | SSTR4 2526/4885SSTR1 2927/4885SSTR2 3381/4885 |
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | SSTR4 1328/4885SSTR1 700/4885SSTR2 871/4885 |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CCR2, CCR1, CCL2 | SSTR4 2207/4885SSTR1 1739/4885SSTR2 2713/4885 |
| US-20230226040-A1 | COMBINATION THERAPY COMPRISING AN FGFR INHIBITOR AND A KRAS INHIBITOR | KRAS, FGFR2, FGFR3 | SSTR4 2292/4885SSTR1 2836/4885SSTR2 2587/4885 |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | SSTR4 3379/4885SSTR1 2134/4885SSTR2 3011/4885 |
| US-20080107625-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, HCCS, VIP | SSTR4 2296/4885SSTR1 2767/4885SSTR2 3073/4885 |
| US-20080161345-A1 | Aryl Sulfonamides | CCR2, CCL2, CX3CR1 | SSTR4 953/4885SSTR1 832/4885SSTR2 751/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | SSTR4 2673/4885SSTR1 2128/4885SSTR2 1622/4885 |
| US-11807624-B2 | Substituted pyrimidinones as agonists of the APJ receptor | APLNR, AGTR1, AGTR2 | SSTR4 804/4885SSTR1 373/4885SSTR2 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.